CoChat

The BET family in immunity and disease

Open access
Wang, Nian, Wu, Runliu, Tang, Daolin, Kang, Rui · 2021 · Signal Transduction and Targeted Therapy

The DOI matches its Crossref record; 200 of the 200 references it cites were found in a registry or an index.

Abstract

Innate immunity serves as the rapid and first-line defense against invading pathogens, and this process can be regulated at various levels, including epigenetic mechanisms. The bromodomain and extraterminal domain (BET) family of proteins consists of four conserved mammalian members (BRD2, BRD3, BRD4, and BRDT) that regulate the expression of many immunity-associated genes and pathways. In particular, in response to infection and sterile inflammation, abnormally expressed or dysfunctional BETs are involved in the activation of pattern recognition receptor (e.g., TLR, NLR, and CGAS) pathways, thereby linking chromatin machinery to innate immunity under disease or pathological conditions. Mechanistically, the BET family controls the transcription of a wide range of proinflammatory and immunoregulatory genes by recognizing acetylated histones (mainly H3 and H4) and recruiting transcription factors (e.g., RELA) and transcription elongation complex (e.g., P-TEFb) to the chromatin, thereby promoting the phosphorylation of RNA polymerase II and subsequent transcription initiation and elongation. This review covers the accumulating data about the roles of the BET family in innate immunity, and discusses the attractive prospect of manipulating the BET family as a new treatment for disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41392-020-00384-4

Cites

200 of 200 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Domain architecture of BET family proteins in human (h), mouse (m), Drosophila (d), and yeast (y). Numbers indicate the amino acid boundaries of each domain in individual proteins. Alignment of amino acid sequences was based on published information using the following accession numbers retrieved from GenBank databases: hBRD2, NM_005104; hBRD3, NM_007371.4; hBRD4-L, NM_058243; hBRD4-S, NM_014299; hBRDT, NM_001242805; mBRD2, NM_010238; mBRD3, NM_001113574; mBRD4-L, NM_020508; mBRD4-S, NM_198094; mBRDT, NM_014299; dfs(1)h, NM_078523; yBdf1, NM_001182287; yBdf2, AJV11655. Abbreviations: BD1, the first bromodomain; BD2, the second bromodomain; Bdf1, chromatin-binding protein BDF1; BRD, bromodomain protein (numbers 2–4); CTD, C-terminal domain; ET, extraterminal domain; Fs(1)h, female sterile (1) homeotic
Fig. 1 Domain architecture of BET family proteins in human (h), mouse (m), Drosophila (d), and yeast (y). Numbers indicate the amino acid boundaries of each domain in individual proteins. Alignment of amino acid sequences was based on published information using the following accession numbers retrieved from GenBank databases: hBRD2, NM_005104; hBRD3, NM_007371.4; hBRD4-L, NM_058243; hBRD4-S, NM_014299; hBRDT, NM_001242805; mBRD2, NM_010238; mBRD3, NM_001113574; mBRD4-L, NM_020508; mBRD4-S, NM_198094; mBRDT, NM_014299; dfs(1)h, NM_078523; yBdf1, NM_001182287; yBdf2, AJV11655. Abbreviations: BD1, the first bromodomain; BD2, the second bromodomain; Bdf1, chromatin-binding protein BDF1; BRD, bromodomain protein (numbers 2–4); CTD, C-terminal domain; ET, extraterminal domain; Fs(1)h, female sterile (1) homeoticCC BY · PubMed Central
Fig. 2 The role BRD4 in regulating the NF-κB pathway in inflammation and immunity. BRD4 regulates the activation of the NF-κB pathway caused by TLR ligands through at least four pathways: (1) BRD4 directly acetylates RELA through its atypical histone acetyltransferase activity; (2) BRD4 directly promotes the phosphorylation of RELA; and (3–4) BRD4 promotes the phosphorylation of RELA through inhibiting the translation of NFKBIA and increasing the phosphorylation of NFKBIA and IKBKB. Abbreviations: CDK9, cyclin-dependent kinase 9; CHUK, component of inhibitor of nuclear factor kappa B kinase complex; CycT1, cyclin T1; IKBKB, inhibitor of nuclear factor kappa B kinase regulatory subunit beta; IKBKG, inhibitor of nuclear factor kappa B kinase regulatory subunit gamma; NFKBIA, NFKB inhibitor alpha; NFKB1, nuclear factor kappa B subunit 1; p-TEFb, positive transcription elongation factor b; RELA, RELA proto-oncogene; RNA pol II, RNA polymerase II; TLR, toll-like receptor (numbers 1–9)
Fig. 2 The role BRD4 in regulating the NF-κB pathway in inflammation and immunity. BRD4 regulates the activation of the NF-κB pathway caused by TLR ligands through at least four pathways: (1) BRD4 directly acetylates RELA through its atypical histone acetyltransferase activity; (2) BRD4 directly promotes the phosphorylation of RELA; and (3–4) BRD4 promotes the phosphorylation of RELA through inhibiting the translation of NFKBIA and increasing the phosphorylation of NFKBIA and IKBKB. Abbreviations: CDK9, cyclin-dependent kinase 9; CHUK, component of inhibitor of nuclear factor kappa B kinase complex; CycT1, cyclin T1; IKBKB, inhibitor of nuclear factor kappa B kinase regulatory subunit beta; IKBKG, inhibitor of nuclear factor kappa B kinase regulatory subunit gamma; NFKBIA, NFKB inhibitor alpha; NFKB1, nuclear factor kappa B subunit 1; p-TEFb, positive transcription elongation factor b; RELA, RELA proto-oncogene; RNA pol II, RNA polymerase II; TLR, toll-like receptor (numbers 1–9)CC BY · PubMed Central
Fig. 3 The role BRD4 in regulating the NLRP3 pathway in inflammation and pyroptosis. a In TNF-primed rat nucleus pulposus cells, in which monosodium urate induced acute gouty arthritis, and middle cerebral artery occlusion induced glial activation, BRD4 inhibits RELA-mediated NLRP3 transcription and subsequent CASP1-dependent inflammasome activation. b In renal cell carcinoma tissues and cells, BRD4 is required for RELA-mediated NLRP3 transcription and subsequent CASP1-dependent inflammasome activation and GSDMD-mediated pyroptosis. Abbreviations: BETi, bromodomain and extraterminal inhibitor; BRD4, bromodomain containing 4; CASP1, caspase 1; GSDMD, gasdermin D; GSDMD-NT, gasdermin D N-terminal domain; IL1B, interleukin 1 beta; IL18, interleukin 18; NLRP3, NLR family pyrin domain containing 3; PYCARD, PYD and CARD domain containing; RELA, RELA proto-oncogene; TNF, tumor necrosis factor
Fig. 3 The role BRD4 in regulating the NLRP3 pathway in inflammation and pyroptosis. a In TNF-primed rat nucleus pulposus cells, in which monosodium urate induced acute gouty arthritis, and middle cerebral artery occlusion induced glial activation, BRD4 inhibits RELA-mediated NLRP3 transcription and subsequent CASP1-dependent inflammasome activation. b In renal cell carcinoma tissues and cells, BRD4 is required for RELA-mediated NLRP3 transcription and subsequent CASP1-dependent inflammasome activation and GSDMD-mediated pyroptosis. Abbreviations: BETi, bromodomain and extraterminal inhibitor; BRD4, bromodomain containing 4; CASP1, caspase 1; GSDMD, gasdermin D; GSDMD-NT, gasdermin D N-terminal domain; IL1B, interleukin 1 beta; IL18, interleukin 18; NLRP3, NLR family pyrin domain containing 3; PYCARD, PYD and CARD domain containing; RELA, RELA proto-oncogene; TNF, tumor necrosis factorCC BY · PubMed Central
Fig. 4 The role of BRD4 in regulating the STING1 pathway in antiviral immunity. Cytoplasmic DNA derived from various viruses activates CGAS and produces endogenous cyclic dinucleotide cGAMP, which binds to STING1 located in the endoplasmic reticulum, and then promotes the dimerization and translocation of STING1 from the ER to the perinuclear region. During trafficking, STING1 recruits and activates TBK1, stimulates the phosphorylation and nuclear translocation of IRF3, and to a lesser extent NFKB1, which leads to the production of type 1 IFN and other inflammatory cytokines (e.g., IL). The nuclear activity of IRF3 and NFKB1 is inhibited by BRD4. In addition, after BRD4 inhibition, the activation of DDR can induce the release of host dsDNA from the nucleus to the cytoplasm, leading to further activation of the CGAS-STING1 pathway to limit viral infection. Abbreviations: BRD4, bromodomain containing 4; cGAMP, cyclic GMP-AMP; CGAS, cyclic GMP-AMP synthase; DDR, DNA damage response; dsDNA, double-stranded DNA; IFN, interferon; IL, interleukin; IRF3, interferon regulatory factor 3; NFKB1, nuclear factor kappa B subunit 1; STING1, stimulator of interferon response cGAMP interactor 1; TBK1, TANK binding kinase 1
Fig. 4 The role of BRD4 in regulating the STING1 pathway in antiviral immunity. Cytoplasmic DNA derived from various viruses activates CGAS and produces endogenous cyclic dinucleotide cGAMP, which binds to STING1 located in the endoplasmic reticulum, and then promotes the dimerization and translocation of STING1 from the ER to the perinuclear region. During trafficking, STING1 recruits and activates TBK1, stimulates the phosphorylation and nuclear translocation of IRF3, and to a lesser extent NFKB1, which leads to the production of type 1 IFN and other inflammatory cytokines (e.g., IL). The nuclear activity of IRF3 and NFKB1 is inhibited by BRD4. In addition, after BRD4 inhibition, the activation of DDR can induce the release of host dsDNA from the nucleus to the cytoplasm, leading to further activation of the CGAS-STING1 pathway to limit viral infection. Abbreviations: BRD4, bromodomain containing 4; cGAMP, cyclic GMP-AMP; CGAS, cyclic GMP-AMP synthase; DDR, DNA damage response; dsDNA, double-stranded DNA; IFN, interferon; IL, interleukin; IRF3, interferon regulatory factor 3; NFKB1, nuclear factor kappa B subunit 1; STING1, stimulator of interferon response cGAMP interactor 1; TBK1, TANK binding kinase 1CC BY · PubMed Central
Fig. 5 The role of BETs in regulating the expression of immune genes mediated by transcription factors. Abbreviations: ACOD1, aconitate decarboxylase 1; AIRE, autoimmune regulator; ALOX12, arachidonate 12-lipoxygenase, 12 S type; BATF, basic leucine zipper ATF-like transcription factor; CCL, C-C motif chemokine ligand (numbers 2–12); CCN2, cellular communication network factor 2; CD, CD molecule (numbers 4–274); CD40LG, CD40 ligand; CDX2, caudal-type homeobox 2; CEBPA, CCAAT enhancer binding protein alpha; CELF2, CUGBP Elav-like family member 2; CMPK2, cytidine/uridine monophosphate kinase 2; CSF1, colony stimulating factor (numbers 1–3); CXCL9, C-X-C motif chemokine ligand 9; E2F1, E2F transcription factor 1; EGR2, early growth response 2; ESM1, endothelial cell-specific molecule 1; ETS1, ETS proto-oncogene 1; FGF2, fibroblast growth factor 2; FLT1, fms-related receptor tyrosine kinase 1; FOXL1, forkhead box L1; FOXM1, forkhead box M1; FOXO3, forkhead box O3; FOXP1, forkhead box P1; FST, follistatin; ICAM1, intercellular adhesion molecule 1; ICOS, inducible T-cell costimulatory; IFIT2, interferon-induced protein with tetratricopeptide repeats 2; IFNB1, interferon beta 1; IL1B, interleukin 1 beta; IL, interleukin (numbers 4–22, including “A” variants); INS, insulin; IRF, interferon regulatory factor; JUN, Jun proto-oncogene, AP-1 transcription factor subunit; KRT13, keratin 13; LIN54, lin-54 DREAM MuvB core complex component; MX1, MX dynamin-like GTPase 1; MYC, MYC proto-oncogene, bHLH transcription factor; NECTIN2, nectin cell adhesion molecule 2; NLRP3, NLR family pyrin domain containing 3; NPPB, natriuretic peptide B; PLK1, polo-like kinase 1; PPARG, peroxisome proliferator activated receptor gamma; PTHLH, parathyroid hormone-like hormone; PVR, PVR cell adhesion molecule; RBPJ, recombination signal binding protein for immunoglobulin kappa J region; RELA, RELA proto-oncogene, NF-κB subunit; RORC, RAR-related orphan receptor C; RUNX2, RUNX family transcription factor 2; S100A9, S100 calcium-binding protein A9; SLPI, secretory leukocyte peptidase inhibitor; SP7, Sp7 transcription factor; SPRY2, sprouty RTK signaling antagonist 2; STAT, signal transducer and activator of transcription; TGIF1, TGFB-induced factor homeobox 1; TNF, tumor necrosis factor; TP53, tumor protein p53; ULBP1, UL16 binding protein (numbers 1–3)
Fig. 5 The role of BETs in regulating the expression of immune genes mediated by transcription factors. Abbreviations: ACOD1, aconitate decarboxylase 1; AIRE, autoimmune regulator; ALOX12, arachidonate 12-lipoxygenase, 12 S type; BATF, basic leucine zipper ATF-like transcription factor; CCL, C-C motif chemokine ligand (numbers 2–12); CCN2, cellular communication network factor 2; CD, CD molecule (numbers 4–274); CD40LG, CD40 ligand; CDX2, caudal-type homeobox 2; CEBPA, CCAAT enhancer binding protein alpha; CELF2, CUGBP Elav-like family member 2; CMPK2, cytidine/uridine monophosphate kinase 2; CSF1, colony stimulating factor (numbers 1–3); CXCL9, C-X-C motif chemokine ligand 9; E2F1, E2F transcription factor 1; EGR2, early growth response 2; ESM1, endothelial cell-specific molecule 1; ETS1, ETS proto-oncogene 1; FGF2, fibroblast growth factor 2; FLT1, fms-related receptor tyrosine kinase 1; FOXL1, forkhead box L1; FOXM1, forkhead box M1; FOXO3, forkhead box O3; FOXP1, forkhead box P1; FST, follistatin; ICAM1, intercellular adhesion molecule 1; ICOS, inducible T-cell costimulatory; IFIT2, interferon-induced protein with tetratricopeptide repeats 2; IFNB1, interferon beta 1; IL1B, interleukin 1 beta; IL, interleukin (numbers 4–22, including “A” variants); INS, insulin; IRF, interferon regulatory factor; JUN, Jun proto-oncogene, AP-1 transcription factor subunit; KRT13, keratin 13; LIN54, lin-54 DREAM MuvB core complex component; MX1, MX dynamin-like GTPase 1; MYC, MYC proto-oncogene, bHLH transcription factor; NECTIN2, nectin cell adhesion molecule 2; NLRP3, NLR family pyrin domain containing 3; NPPB, natriuretic peptide B; PLK1, polo-like kinase 1; PPARG, peroxisome proliferator activated receptor gamma; PTHLH, parathyroid hormone-like hormone; PVR, PVR cell adhesion molecule; RBPJ, recombination signal binding protein for immunoglobulin kappa J region; RELA, RELA proto-oncogene, NF-κB subunit; RORC, RAR-related orphan receptor C; RUNX2, RUNX family transcription factor 2; S100A9, S100 calcium-binding protein A9; SLPI, secretory leukocyte peptidase inhibitor; SP7, Sp7 transcription factor; SPRY2, sprouty RTK signaling antagonist 2; STAT, signal transducer and activator of transcription; TGIF1, TGFB-induced factor homeobox 1; TNF, tumor necrosis factor; TP53, tumor protein p53; ULBP1, UL16 binding protein (numbers 1–3)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 200 references

Cited by

See all 329

Metadata

Authors
Wang, N., Wu, R., Tang, D., & Kang, R.
Affiliations
The University of Texas Southwestern Medical Center (US)
Corresponding author
  • Tang, Daolin
  • Kang, Rui
Venue
Signal Transduction and Targeted Therapy
Published
2021-01-19
Volume
6
Issue
1
Pages
23-23
ISSN
2059-3635 (ISSN-L)
OpenAlex
W3121466164
Cited by
295
References
200
Citations by year
2026: 33 · 2025: 67 · 2024: 60 · 2023: 57 · 2022: 50 · 2021: 28
FWCI
5.20
Type
journal article
Language
en
Open access
Licence
Locations
  • Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • University of Texas Southwestern Medical Center
  • National Institutes of Health
  • National Cancer Institute (R01CA211070)
  • National Institute of General Medical Sciences (R01GM127791)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
Keywords
BET proteins, BRD2, BRD3, BRD4, BRDT, innate immunity, epigenetic regulation, histone acetylation, pattern recognition receptors, Toll-like receptors, sterile inflammation, P-TEFb, RNA polymerase II elongation, RelA, chromatin regulation, BET inhibitors, immunotherapy
MeSH terms
Animals, Chromatin, Humans, Immunity, Innate, Transcription Factors, Transcription, Genetic, Epigenesis, Genetic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The BET family in immunity and disease. https://app.cochat.ai/papers/10.1038/s41392-020-00384-4
The paper
Wang, N., Wu, R., Tang, D., & Kang, R. (2021). The BET family in immunity and disease. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-020-00384-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.